Myriad Genetics, Inc. MYGN is well-poised to grow in the coming quarters due to its impressive cadence of product launches. The company is also progressing well in its refreshed long-term strategy to ...

The global cell therapy market was valued at $5.88 billion in 2024 and is on track to hit $44.39 billion by 2034, expanding at a striking 22.69% CAGR. Researchers credit this explosive growth to ...

Also Read: Vinay Prasad’s Appointment To FDA’s CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation Additionally, the company revealed clinical data from Part A of the REVEAL Phase ...

GeneDx stock (NASDAQ: WGS) plunged 14% on Monday after the genomics testing company released preliminary full-year 2025 results that met expectations. But the company unveiled 2026 guidance that ...

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where bluebird bio, Inc. (NASDAQ:BLUE) stands against the other gene ...

Discoveries made by companies in the genetics sector help support every other life science industry in a variety of ways. One of the genetic sector's major contributions is the discovery of new ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands ...